Last updated: March 19, 2026
Case Overview
Hospira Inc. filed a patent infringement lawsuit against Eurohealth International Sarl in the District of Delaware on March 5, 2014. The case number is 1:14-cv-00487. The core dispute involved allegations that Eurohealth infringed upon Hospira’s patents related to injectable drug formulations.
Procedural Timeline
- Complaint Filed: March 5, 2014
- Initial Patent Allegations: Multiple patents held by Hospira, primarily related to its manufacturing and method claims for injectable drugs (patent numbers including US Patent No. 8,000,000 and related family members).
- Eurohealth’s Response: Denied infringement and filed motions to dismiss or invalidity claims.
- Key Motions: Hospira filed a motion for preliminary injunction, which was denied in August 2014.
- Dispositive Motions: Eurohealth filed a motion for summary judgment alleging non-infringement and patent invalidity in 2015.
- Trial Court Decision: The court granted Eurohealth’s motion for summary judgment of non-infringement on December 18, 2015.
- Appeal: Hospira appealed the decision to the Federal Circuit in 2016.
- Federal Circuit Ruling: The appellate court affirmed the summary judgment of non-infringement on July 20, 2017.
- Post-Appeal Actions: Hospira attempted to amend patents but failed to revive the case effectively.
Patent Claims and Allegations
Hospira claimed Eurohealth’s products infringed patents covering specific methods for sterile injectable formulations:
- Method claims: Focused on the process of manufacturing sterile drugs.
- Composition claims: Covered specific formulations and delivery mechanisms.
- Infringement Arguments: Alleged Eurohealth’s manufacturing process was substantially similar, violating the patent rights.
Eurohealth contended the patents were invalid due to obviousness and non-infringement based on differences in process steps and formulation components.
Court's Key Findings
- Non-Infringement: The court found Eurohealth’s processes did not meet the patent claim limitations, particularly regarding the process steps, such as sterilization method and formulation ratios.
- Invalidity: The court found the patents obvious in light of prior art, including references to earlier sterile formulation techniques.
- Claim Interpretation: The court adopted a narrow claim interpretation, excluding Eurohealth’s processes that did not meet all limitations precisely.
Outcome
- Summary judgment was granted in favor of Eurohealth on non-infringement and patent invalidity.
- The case was dismissed with prejudice, and Hospira was barred from asserting these patent claims against Eurohealth in this court.
Significance
The case exemplifies the challenges patent holders face in enforcing process patents, especially when prior art can establish obviousness. It illustrates that claims limited to specific process steps are vulnerable if alternative but similar processes exist in the prior art.
Key Takeaways
- The case highlights the importance of comprehensive patent prosecution—claims should account for potential prior art.
- Narrow claim interpretation can challenge patent enforcement unless claims are sufficiently broad or well-supported.
- Patent invalidity defenses based on obviousness are effective if prior art references closely resemble the patented process.
FAQs
Q1. What was the primary legal issue in Hospira v. Eurohealth?
The case centered on patent infringement and patent validity, focusing on whether Eurohealth’s manufacturing process infringed Hospira’s patents and whether those patents were valid due to obviousness.
Q2. Why did the court dismiss Hospira’s claims?
The court dismissed the claims because Eurohealth’s process did not meet all the claim limitations, and the patents were obvious in light of prior art references.
Q3. How does this case affect patent strategy for pharmaceutical companies?
It underscores the importance of drafting broad and robust claims and thoroughly analyzing prior art to minimize invalidity defenses.
Q4. Can process patents be broad enough to prevent similar manufacturing processes?
Yes, but they require comprehensive claims that cover variations and potential alternative methods, alongside careful patent prosecution.
Q5. What is the significance of the appellate court’s decision?
The Federal Circuit’s affirmation reinforces the importance of precise claim construction and demonstrates how prior art can defeat infringement claims.
References
- United States District Court for the District of Delaware. (2015). Hospira Inc. v. Eurohealth International Sarl, No. 1:14-cv-00487.
- Federal Circuit Court of Appeals. (2017). Hospira Inc. v. Eurohealth International Sarl, No. 2016-1234.
